Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs

This article was originally published in Scrip

Executive Summary

Amgen traded certain ex-US rights to its Phase III calcitonin gene-related peptide (CGRP) inhibitor for migraine headaches to acquire shared global rights to Novartis's early-stage candidate for Alzheimer's disease, raising an important question: Who is getting the better deal?

Advertisement

Related Content

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success
Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data
Amgen/Novartis CGRP Inhibitor Migraine Data Underwhelm Ahead Of Phase III Apex

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel